Used in research settings to study glycine transporter type 1 (GlyT1) inhibition, which plays a role in modulating NMDA receptor activity. This makes it relevant for investigating potential treatments for neurological and psychiatric disorders such as schizophrenia, cognitive impairments, and depression. It serves as a tool compound in preclinical studies to understand neurotransmission and synaptic plasticity. Due to its selectivity, it helps scientists explore the therapeutic effects of enhancing glutamatergic signaling without direct receptor activation. Not intended for clinical use or human consumption.